Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06618313
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-26
Brief Title:
One Trial to Evaluate the Safety Tolerability and Efficacy of JCXH-213 in Patients With rr B-NHL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Open-label Single-armExploratory Clinical Trial to Evaluate the Safety Tolerability and Efficacy of JCXH-213 in Patients With RelapsedRefractory B-cell Non-Hodgkin Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the Safety and Efficacy of JCXH-213 in Patients with RelapsedRefractory B-cell non-Hodgkin Lymphoma
Detailed Description:
Patient will receive study treatment in the treatment observation period After the end of the treatment observation period patients will be allowed to continue to receive treatment if there is no major safety problems and the investigator judges that the patient may continue to benefit
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None